Today's Edition
ABU DHABI (ALETIHAD)
Cleveland Clinic Abu Dhabi has introduced the first robotically-assisted bronchoscopy technology in the Middle East, enabling access to the smallest lung nodules deep within the lungs, often the earliest visible signs of lung cancer, supporting accurate diagnosis at early stages without the need for open surgery.
The MONARCH platform enables physicians to guide the bronchoscopy deep into the lungs with enhanced stability and precision, while targeting nodules for biopsy in real time.
This supports earlier diagnosis and strengthens the ability to intervene at the right time with more targeted treatment strategies.
For patients, these capabilities translate into a safer, less invasive care experience, with faster and more accurate diagnosis, ultimately improving clinical outcomes and quality of life.
The introduction of this technology is supported by the Department of Health – Abu Dhabi, which continues to accelerate the adoption of advanced healthcare technologies with tangible impact on patients, reflecting Abu Dhabi’s broader vision to build a proactive healthcare ecosystem and shift from reactive treatment to prediction, early detection and prevention.
Chief Executive Officer at Cleveland Clinic Abu Dhabi, Dr Georges-Pascal Haber, said, “Introducing robotically-assisted bronchoscopy reflects Cleveland Clinic Abu Dhabi’s continued commitment to bringing transformative, precision-led technologies to the Middle East region. By investing in advanced, technology-enabled solutions, we are redefining patients’ experience through safer, less invasive care while also enhancing diagnostic accuracy.”
Commenting on the impact of this innovation, Division Chair, Pulmonary Medicine, Integrated Hospital Care Institute in Cleveland Clinic Abu Dhabi, Dr Zaid Zoumot, said, “Robotically-assisted bronchoscopy represents a breakthrough in how we detect and diagnose lung disease. For the first time, we can precisely access and biopsy even the smallest, most difficult-to-reach lung nodules, enabling diagnosis at earlier stages where lung cancer is most treatable, and outcomes are better.”
In addition to supporting early detection of lung cancer at Stage 1, where survival rates improve significantly, exceeding 70 per cent, this technology can also be used to diagnose lung nodules arising from cancer that has metastasised to the lungs, benign lung nodules, infections such as tuberculosis, and inflammatory lung diseases.
In the future, this technology could also assist with robotic surgical interventions for cancer and the treatment of detected nodules through ablation, heat, or cold therapy.
With the introduction of robotically-assisted bronchoscopy to the Middle East, Cleveland Clinic Abu Dhabi is expanding access to advanced, minimally invasive diagnostic technologies, delivering earlier diagnoses, more precise care, and better outcomes for patients in Abu Dhabi and beyond.
